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Background: Incidence rates of various cancers are increasing in Arab countries and are expected to reach those
of industrialized ones in few decades. This paper aimed to describe the incidence rates of most common
cancers - and/or of those cancer preventable through modifiable behaviors - recorded in the province of Setif,
Algeria from 1986 through 2010.
Methods: Cancer diagnoses for the 1986–2010 period were provided by the population-based Cancer Registry
of Setif, disentangled by site, morphology, age (quinquennia), sex, and calendar period. The corresponding
population was obtained from the Algerian Institute of Statistics. Age-standardized rates (world population)
(ASR-WR) were computed by calendar period (five quinquennias from 1986–1990 to 2006–2010), while annual
percent changes (APCs) were computed for the period 1996–2010.
Results: During the 2006–2010 period, ASR-WR for all cancer sites were 106.4/100,000 in men and 110.3 in
women. The four leading cancers were: lung (18.0%); colon-rectum (9.6%); bladder (9.1%); and prostate (6.5%) in
men; breast (36.4%); colon-rectum (8.5%); cervix uteri (6.0%); and thyroid (6.0%) in women. Between 1996–2010,
overall cancer incidence increased statistically significantly (p < 0.05) in both men (APC = +2.5%) and women
(APC = +3.7%). Statistically significant decreasing trends were observed for nasopharyngeal carcinoma (APC =−3.4%) in
men, and for cervical (APC = −4.2%) and gallbladder (APC = −3.2%) cancers in women. Statistically significant increasing
trends were observed for most common cancers both in men (lung:+1.8%, colon-rectum:+5.4%, prostate:+4.3%,
liver:+8.9%, and bladder:+5.9%) and women (breast:+8.2%, colon-rectum:+4.5%, lung:+10.0%, liver:+5.4%,
thyroid:+5.3%, and larynx:+13.8%).
Conclusions: International recommendations against cancer must be strongly promoted in Setif after taking
into account epidemiological transition, lifestyle, and environmental changes.
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Cancer rates in northern Arab countries lying on the
African side of the Mediterranean Sea are substantially
lower than those reported in European Mediterranean
countries such as Spain, France or Italy [1]. However,
some increases in cancer incidence in northern African
countries (e.g., Algeria, and Tunisia) have been recently
observed for some cancer sites [2-5]. Although still one* Correspondence: bidolie@cro.it
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distribution, and reproduction in any mediumthird or one half lower than those of industrialized
countries, incidence rates are expected to rise and to
reach similar levels in few decades. Furthermore, varia-
tions in overall rates among those countries were by far
smaller than the differences between this group of countries
and Europe [6]. A substantial proportion of these increasing
cancer rates is potentially avoidable by primary and second-
ary prevention programs, while improvements in diagnosis
and anticancer treatments would increase survival. In
Algeria, cancer has become a national priority bringing to a
2014–20 national cancer plan under aegis of the President
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recording incidence data for the whole Wilaya (province)
of Setif, the second in size after the Wilaya of Algiers -
the capital city of Algeria. An accurate description of
temporal trends by cancer site can contribute to a better
understanding of cancer incidence patterns and their po-
tential etiology and/or prevention. We took advantage of
the availability of computerized incidence data recorded
in CR-S over the 1986–2010 period to describe trends in
incidence for the most common cancer sites and/or for
the potentially preventable ones.
Methods
Data regarding all incident cancer cases diagnosed dur-
ing the period 1986–2010 derived from the population-
based cancer registry of Setif, established in 1989 in
collaboration with the International Agency for Research
on Cancer (IARC). The Director of the Cancer Registry
of Setif (Prof. Hamdi Cherif ) approved the use of the
registry data for the purposes of the study. Nowadays,
the CR-S covers a population of about 1.5 million inhab-
itants (as attested by 2008 national census), which is
nearly 5% of the Algerian population. Collection of data
is primarily active.
For the aims of this analysis, incidence data were dis-
entangled by age (quinquennia), sex and type of cancer.
The International Classification of Diseases for Oncology,
second version (ICD-O-3), was used for cancer classifica-
tion [7]. The ICD-O-3 codes were translated to ICD-10 for
data analysis. Registration validity and completeness were
evaluated using percentage of microscopic verification
(MV) index (the proportion of incident cases with histo-
logical and/or cytological verification of cancer diagnosis)
and percentage of death certificates only (DCO) (the pro-
portion of incident cases with information based on death
certificates only). For all cancers the MV was 96.2% (ran-
ging from 93.4% in lung cancer to 98.8% in breast cancer),
while the proportion of DCO was 1.2% (ranging from 0.2%
for cervical cancer to 3% in leukemias). To improve validity
and comparability of some cancer sites/types with other
populations that used previous cancer classifications [8,9],
we summed-up case frequencies of intestinal sites, non-
Hodgkin’s lymphomas, and leukemias. In particular, the
statistical analysis focused on the following cancers, or
groups of cancers (ICD-10): nasopharynx (C11), stomach
(C16), colon-rectum (C18–21), liver (C22), gallbladder
(C23-24), larynx (C32), lung (C33–34), prostate (C61),
breast (C50), cervix uteri (C53), corpus uteri (C54), uterus
unspecified (C55), ovary (C56), kidney and other urinary
sites (C64-66, C68), bladder (C67), thyroid (C73), Hodgkin’s
lymphoma (C81), non-Hodgkin’s lymphomas (C82–85,
C96), all leukemia (C91–95), unspecified or ill-defined can-
cers (C26, 39, 48, 58, 76, 77, 80), and all malignant cancers
excluding skin carcinoma (C00-97, but C44). Corpus uteriand uteri unspecified were only examined to quantify any
classification shift between uterus sub-sites during the study
period.
The structure of the resident population by sex, age,
and calendar year was abstracted from the Algerian In-
stitute of Statistics database [www.ons.dz].
Incidence data were grouped into five quinquennia of
calendar years (1986–1990, 1991–1995, 1996–2000, 2001–
2005, and 2006–2010). Age-standardized incidence rates
per 100,000 (to the world standard population) [10]
(ASR-WR) were calculated in both sexes by the five
quinquennia described - or for each calendar year from
1996 to 2010 - according to selected cancers or groups of
cancers. Incidence rates and their corresponding standard
errors were calculated using SEER*Stat (Surveillance
Research Program, National Cancer Institute SEER*Stat
software, seer.cancer.gov/seerstat, version 8.1.2).
The computation of annual percent change (APC)
[11,12] of incidence rates was restricted to the 1996–
2010 period, to specifically quantify the recent impact of
cancer incidence on the Setif population. APCs were
calculated separately by age groups (15–44 years, 45–64
years, and 65+ years) and in the total population. APCs
were estimated by fitting a linear regression line to the
natural logarithm of annual incidence rates using calen-
dar year as a regressor variable. This calculation assumes
that the incidence rates changed at a constant rate over
the entire calendar-year interval examined, and the validity
of this assumption was checked by merely examining plot-
ted curves. APCs were computed using the Joinpoint
software and their statistical significance (p < 0.05) was cal-
culated by means of a Student’s t-distribution [12].
Results and discussion
The overall number of incident cancers (all cancers, ex-
cluding skin carcinoma) diagnosed in the Wilaya of Setif
during the period 2006–2010 was 6235 (2883 men and
3352 women) corresponding to an ASR-WR (per 100,000)
of 106.4 in men and 110.3 in women (Table 1). Nearly 70%
of overall cancer incidence was attributable in both sexes,
to few leading cancers, namely: lung (18.0%); colon-rectum
(9.6%); bladder (9.1%); prostate (6.5%); stomach (5.5%);
non-Hodgkin’s lymphomas (5.5%); larynx (5.3%); nasophar-
ynx (5.0%); and leukemias (4.8%) in men. In women, the
major sites were breast (36.4%); colon-rectum (8.5%); cervix
uteri (6.0%); thyroid (6.0%); gallbladder (4.4%); lung (3.6%);
non-Hodgkin’s lymphomas (3.3%) and leukemias (3.2%)
(Table 1). By contrast, these cancers explained a lower
proportion of overall cancers during the period 1986–90
(64% in men and 57% in women).
Throughout the study period (25 years), overall cancer
incidence rates steadily increased in both sexes (Table 1).
In men, rates (per 100,000) increased from 67.9 in
1986–1990 to 106.4 in 2006–2010 while in women rates
Table 1 Number of incident cases and age-adjusted standardized rates (world population) (ASR-WR) of selected cancers
by sex according to calendar period (quinquennia), Sétif Cancer Registry
Cancer or group of cancers
Period
1986-1990 1991-1995 1996-2000 2001-2005 2006-2010
N ASR-WR/105 N ASR-WR/105 N ASR-WR/105 N ASR-WR/105 N % ASR-WR/105
Men
Nasopharynx 78 4.5 121 5.9 169 7.3 170 6.4 144 5.0 4.8
Stomach 146 9.8 131 8.1 143 7.0 142 6.6 159 5.5 6.1
Colon-rectum 33 2.1 58 3.4 136 5.9 189 8.1 277 9.6 9.9
Liver 60 4.0 36 2.3 11 0.6 35 1.7 53 1.8 2.1
Gallbladder 30 2.0 32 2.0 30 1.6 60 2.9 52 1.8 2.1
Larynx 45 3.1 55 3.6 98 5.3 137 6.7 153 5.3 5.9
Lung 181 12.7 242 15.8 308 17.1 414 20.2 518 18.0 21.1
Prostate 25 1.7 39 2.6 90 5.1 101 4.8 188 6.5 7.6
Kidney 7 0.3 12 0.7 17 0.7 26 1.2 26 0.9 0.9
Bladder 25 1.6 31 1.9 100 5.7 164 8.1 262 9.1 10.3
Thyroid 5 0.3 5 0.2 23 1.0 31 1.2 43 1.5 1.4
Hodgkin lymphoma 43 1.8 51 2.1 42 1.4 103 3.3 67 2.3 1.9
Non Hodgkin lymphomas 60 3.3 80 3.9 123 5.1 107 4.0 158 5.5 5.2
Leukaemias 119 5.1 92 3.7 52 2.2 63 2.4 139 4.8 4.6
Unspecified and ill-defined cancers 86 5.4 70 3.6 85 4.0 76 3.0 119 4.1 4.5
All cancers but skin 1118 67.9 1230 69.3 1683 82.2 2136 93.3 2883 100 106.4
Women
Nasopharynx 41 2.0 60 2.7 49 1.7 63 2.2 69 2.1 2.1
Stomach 79 4.8 57 3.2 64 2.7 81 3.4 80 2.4 2.8
Colon-rectum 39 2.4 59 3.0 142 6.1 213 8.6 285 8.5 9.9
Liver 80 5.1 34 2.0 18 0.9 26 1.1 44 1.3 1.6
Gallbladder 100 6.7 150 8.8 168 8.4 199 9.0 149 4.4 5.7
Larynx 7 0.4 2 0.1 3 0.1 13 0.5 29 0.9 0.9
Lung 30 2.0 34 2.0 38 1.7 50 2.2 121 3.6 4.5
Breast 192 10.6 253 13.6 440 20.2 571 23.1 1221 36.4 39.5
Cervix uteri 156 9.3 221 12.3 222 11.3 239 10.7 201 6.0 7.1
Corpus uteri 13 0.9 16 1.0 26 1.4 6 0.3 8 0.2 0.3
Uterus. unspecified 12 0.8 1 0.1 5 0.3 14 0.6 39 1.2 1.5
Ovary 26 1.4 45 2.3 61 2.5 30 1.1 75 2.2 2.2
Kidney 14 0.6 8 0.3 28 1.0 17 0.7 27 0.8 1.0
Bladder 3 0.2 2 0.1 4 0.2 50 2.2 34 1.0 1.2
Thyroid 22 0.9 31 1.5 81 3.6 145 5.4 200 6.0 6.2
Hodgkin lymphoma 24 0.9 32 1.1 29 0.9 63 1.6 78 2.3 1.9
Non Hodgkin lymphomas 35 1.7 46 2.1 79 3.0 90 3.3 112 3.3 3.4
Leukaemias 77 3.5 76 3.1 50 1.9 56 2.1 107 3.2 3.1
Unspecified and ill-defined cancers 77 4.2 51 2.5 76 3.4 76 3.0 117 3.5 4.1
All cancers but skin 1143 64.4 1292 67.0 1727 77.9 2190 87.8 3352 100 110.3
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tween 1996 and 2010 (last 15 years of observation),
APCs (% per year) increased statistically significantly(p < 0.05) by +2.5 (95%CI:+1.6;+3.4) in men, and by +3.7
(95%:+2.6;+4.8) in women (Table 2). These positive
APCs were consistent across all age groups (15–44
Table 2 Annual Percent Changes (APC), and corresponding 95% Confidence Intervals (CI), of selected cancers by sex
according to age groups, during the period 1996-2010, Sétif Cancer Registry
Cancer or group of cancers All Ages 15-44 years 45-64 years 65+ years
APC 95% CI APC 95% CI APC 95% CI APC 95% CI
Men
Nasopharynx −3.4* (−5.1;-1.6) −4.9* (−8.5;-1.1) −4.0* (−6.8;-1.1) −2.4 (−9.8;+5.6)
Stomach −1.1 (−2.7;+0.6) −7.0* (−12.0;-1.8) −2.0 (−5.9;+2.2) +2.7 (−0.6;+6.1)
Colon-rectum +5.4* (+3.4;+7.6) −0.8 (−4.7;+3.3) +3.7* (+0.5;+7.0) +11.1* (+6.5;+15.8)
Liver +8.9* (+0.9;+17.5) +3.6 (−13.8;+24.6) +1.6 (−7.8;+12.1) +9.6 (−0.4;+20.6)
Gallbladder +1.0 (−5.2;+7.6) −4.3 (−15.3;+8.0) −0.2 (−8.2;+8.5) +3.3 (−4.8;+12.1)
Larynx +1.0 (−4.8;+7.1) +4.7 (−5.9;+16.4) −4.8 (−10.8;+1.6) +5.1 (−0.9;+11.4)
Lung +1.8* (+0.0;+3.6) +4.7 (−3.8;+14.0) +0.7 (−1.6;+3.1) +2.8* (+0.3;+5.4)
Prostate +4.3* (+2.0;+6.8) +1.0 (−18.4;+25.0) +0.9 (−3.7;+5.8) +5.0* (+1.7;+8.5)
Kidney +4.3 (−1.1;+10.0) +0.6 (−14.8;+18.7) +2.0 (−5.5;+10.1) −0.6 (−10.6;+10.6)
Bladder +5.9* (+4.1;+7.7) +7.4 (−1.1;+16.5) +3.5* (+0.4;+6.6) +8.0* (+4.7;+11.5)
Thyroid +3.2 (−3.6;+10.5) +0.1 (−7.6;+8.5) −0.2 (−9.1;+9.6) +2.6 (−7.2;+13.5)
Hodgkin lymphoma −0.6 (−7.8;+7.2) +1.2 (−6.6;+9.6) −1.9 (−11.1;+8.4) +5.4 (−8.0;+20.8)
Non Hodgkin lymphomas +0.8 (−3.3;+5.0) +2.3 (−2.8;+7.7) −1.8 (−8.4;+5.4) +4.4 (−2.7;+11.9)
Leukaemias +6.7 (−0.4;+14.2) +13.7* (+6.8;+21.0) +3.0 (−3.0;+9.4) +6.0 (−4.2;+17.2)
Unspecified and ill-defined cancers +0.5 (−4.2;+5.5) −0.6 (−9.1;+8.6) −1.1 (−6.5;+4.6) +4.4 (−1.7;+10.9)
All cancers but skin +2.5* (+1.6;+3.4) +1.5 (−0.4;+3.4) +0.9 (−0.4;+2.2) +5.1* (+3.8;+6.4)
Women
Nasopharynx +2.5 (−1.6;+6.7) −0.7 (−6.1;+4.9) +5.5 (−1.6;+13.1) +0.0 (−6.7;+7.1)
Stomach +0.6 (−1.7;+2.9) −6.6* (−12.4;-0.4) +0.3 (−4.5;+5.4) +3.3 (−1.8;+8.6)
Colon-rectum +4.5* (+1.6;+7.4) −2.1 (−6.3;+2.3) +5.3* (+1.4;+9.3) +7.5* (+3.8;+11.3)
Liver +5.4* (+0.2;+10.8) +6.6 (−6.0;+20.8) +5.3 (−2.5;+13.8) +3.1 (−4.0;+10.8)
Gallbladder −3.2* (−5.8;-0.5) −8.7* (−14.5;-2.5) −2.8 (−5.8;+0.4) −2.1 (−6.6;+2.7)
Larynx +13.8* (+0.6;+28.7) +22.8 (−1.3;+52.9) +6.7 (−7.7;+23.3) +5.4 (−9.9;+23.2)
Lung +10.0* (+5.9;+14.2) +6.2 (−0.8;+13.6) +10.4* (+3.2;+18.1) +7.8* (+2.8;+13.1)
Breast +8.2* (+5.7;+10.7) +9.7* (+5.8;+13.7) +7.3* (+4.8;+9.9) +6.9* (+1.9;+12.2)
Cervix uteri −4.2* (−6.6;-1.7) −1.8 (−5.7;+2.3) −5.9* (−9.4;-2.3) −0.6 (−4.5;+3.4)
Ovary −2.1 (−6.7;+2.8) −0.0 (−6.1;+6.4) −7.5* (−11.5;-3.3) +0.8 (−5.1;+6.9)
Kidney −3.4 (−11.1;+4.9) +0.1 (−12.7;+14.7) −0.9 (−6.7;+5.2) +5.1 (−9.4;+22.1)
Bladder −4.4 (−15.4;+8.0) +0.1 (−21.8;+28.1) −10.4 (−26.3;+9.0) +4.0 (−5.2;+14.1)
Thyroid +5.3* (+2.8;+7.9) +9.8* (+5.6;+14.2) +5.0* (+1.8;+8.4) −0.8 (−5.3;+3.8)
Hodgkin lymphoma +4.7 (−1.3;+11.1) +3.2 (−1.6;+8.3) −1.2 (−9.3;+7.6) +23.9 (−4.1;+59.9)
Non Hodgkin lymphomas +2.9 (−1.0;+6.9) +6.3* (+0.9;+12.0) +4.1 (−1.1;+9.6) −2.1 (−8.1;+4.3)
Leukaemias +3.1 (−3.9;+10.6) +11.2* (+2.9;+20.1) −0.1 (−7.4;+7.8) +3.6 (−5.3;+13.4)
Unspecified and ill-defined cancers −0.4 (−5.9;+5.4) −5.4 (−11.0;+0.6) −3.2 (−9.1;+3.0) +4.6 (−2.8;+12.7)
All cancers but skin +3.7* (+2.6;+4.8) +5.2* (+3.1;+7.4) +2.8* (+1.6;+4.0) +4.4* (+2.5;+6.4)
*p < 0.05.
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nificant (p < 0.05) APCs in the three age groups in
women and in the 65+ age group in men.
In men, stomach cancer incidence rates decreased
continuously during the whole period. Nasopharyngeal
incidence rates increased up to 1996–2000 and declinedthereafter. Non-Hodgkin’s lymphomas rates increased
up to 1996–2000 and leveled-off thereafter. Cancers of
gallbladder and kidney, Hodgkin lymphomas, leukemias
and ill-defined cancer showed somewhat stable trends dur-
ing the 25 years examined. Liver cancer rates increased
since 1996–2000 after a decrease. Conversely, increased
Hamdi Cherif et al. BMC Cancer 2014, 14:637 Page 5 of 8
http://www.biomedcentral.com/1471-2407/14/637trends were observed for cancer of the colon-rectum, lar-
ynx, lung, prostate, bladder and thyroid (since 1996–2000).
In women, stomach cancer rates declined up to 1996–
2000 and leveled-off thereafter, whereas rates of invasive
cervical cancer increased up to 1991–1995 and declined
thereafter. Gallbladder rates increased up to 2001–2005
and declined thereafter while lung cancer incidence rates
increased after 2001–2005. Cancers of nasopharynx, lar-
ynx, ovary, kidney, and bladder, Hodgkin’s lymphomas,
leukemias and ill-defined cancers showed somewhat
stable trends during the 25 years examined. Liver cancer
rates increased since 1996–2000 after a decrease. By
contrast, cancer of the colon-rectum, breast, and thy-
roid, and non-Hodgkin’s lymphomas increased through-
out the whole period examined.
Furthermore, between 1996 and 2010, cancer inci-
dence rates showed some statistically significant negative
APCs (% per year) (Table 2). Decreases were displayed
for nasopharyngeal cancer (APC = −3.4) in men, and for
gallbladder (−3.2), and cervical cancers (−4.2) in women.
Many statistically significant positive APCs (Table 2)
were observed. Increases in both sexes were observed
for colon-rectum (APC = +5.4 in men and +4.5 in
women), liver (APC = +8.9 in men and +5.4 in women),
and lung (APC = +1.8 in men and +10.0 in women).
Men displayed increases for bladder (APC = +5.9), and
prostate (APC = +4.3) cancers, while women displayed
increases for larynx (APC = +13.8), breast (APC = +8.2),
and thyroid (APC = +5.3) cancers.
Some variability in temporal trends was registered ac-
cording to sex, age groups and cancer site/type. How-
ever, this variability was partially compatible with
random variation due to small number of cases in the
considered strata. The 15–44 age group displayed statis-
tically significant decreases for nasopharynx carcinoma
(APC = −4.9), and stomach cancer (APC = −7.0) in men,
and for stomach (APC = −6.6), and gallbladder (APC = −
8.7) cancers in women. Increases were observed for
leukemias (APC = +13.7) in men, for cancers of the
breast (APC = +9.7), and thyroid (APC = +9.8) and
non-Hodgkin lymphomas (APC = +6.3), and leukemias
(APC = +11.2) in women. The increase of leukemias in-
cidence was mainly related to the increase of lymphoid
leukemias, however no complete information was avail-
able about the type of lymphoid leukemia (acute,
chronic, or other). The 45–64 age group displayed statis-
tically significant decreases for nasopharynx carcinoma
(APC = −4.0), in men, and for cervical (APC = −5.9) and
ovarian (APC = −7.5) cancers in women. Increases were
observed for colon-rectum (APC = +3.7), and bladder
(APC = +3.5) cancers in men, and for colon-rectum
(APC = +5.3), lung (APC = +10.4), breast (APC = +7.3),
and thyroid (APC = +5.0) cancers in women. The 65+
age group displayed exclusively statistically significantpositive APCs for colon-rectum (APC = +11.1), lung
(APC= +2.8), prostate (APC= +5.0), and bladder (APC= +
8.0) cancers in men, and for colon-rectum (APC= +7.5),
lung (APC= +7.8), and breast (APC= +6.9) cancers in
women.
We investigated cancer incidence trends recorded by
the Cancer Registry of the Wilaya of Setif, Algeria,
across a 25 year period (1986–2010). To the best of our
knowledge, this is the first report to investigate a large
number of different types of cancer according to age for
a quarter century in a northern African population.
Decreasing trends were observed for nasopharyngeal
carcinoma in men, and for cervical and gallbladder can-
cers in women, whereas increasing ones were observed
mainly in leading cancers both in men (lung, colon-
rectum, prostate, liver, and bladder) and women (breast,
colon-rectum, lung, liver, thyroid and larynx).
Leading cancers were similar to those reported by
other North-African studies [2-4,6,13,14]. In contrast
with the United States and other Western Countries,
lung, colon-rectum, female breast, and prostate cancers
showed in Setif increasing temporal trends [9]. The ob-
served temporal trends give clues about large scale
changes in exposure to risk factors, and to improve-
ments in opportunistic early diagnosis.
Lung cancer incidence is largely determined by preva-
lence and duration of smoking. In Algeria, between 1970
and 1980, prevalence of smoking increased both for
blond (34 times) and for black (+50%) tobacco. In
addition between 1978 and 2005 prevalence of smoking
increased from 7.7% to 28.6% [3,15,16]. Smoking is also
strongly associated with the occurrence of bladder, kid-
ney, and larynx carcinomas. The increasing trends in in-
cidence of all these cancers in men can thus be ascribed
to the increased prevalence of smoking over time. In
women, the smoking effect is noticeable only for lung
and larynx cancers and an increase of incidence of blad-
der and kidney cancers is likely expected. The sharp
temporal variations observed in laryngeal cancer in
women across age groups are compatible with random
variations linked to small number of incident cases.
Nasopharyngeal carcinoma (NPC) is a rare malignancy
in most regions of the world, but it is endemic in Algeria
and more generally in North Africa. Major risk factors
include Epstein-Barr virus infection, genetic susceptibil-
ity, consumption of salt-preserved fish or other pre-
served foods, a family history of NPC, and tobacco
smoking [17]. In Setif, traditionally preserved food such
as “harissa”, pickled fruits and vegetables, dried and
salted meat or fat, rancid butter, and domestic fumes
have been described as NPC risk factors [16,18-20]. By
contrast XRCC1 and hOGG1 genes are unlikely to play
a role in the susceptibility to NPC in North Africans
[21]. We observed that NPC decreased in men but not
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different pattern across sexes remains outside the scope
of an observational study.
Changes in viral hepatitis prevalence rather than alco-
hol consumption seemed to explain the rise of liver can-
cer incidence because the other alcohol-related cancers
(oral cavity, pharynx or esophagus cancers) were stable,
with ASR-WRs below 1/100.000 (not shown). The
prevalence of hepatitis B virus in blood donors was
around 3.6% in 1989 [3]. To the best of our knowledge,
no other information such as prevalence of hepatitis C
virus is yet available.
Breast cancer, the most common female cancer diag-
nosed in Setif, dropped in all age groups. The reasons
for this shift are unknown, but they may include increases
in the prevalence of risk factors that modify endogenous
levels of sex hormones such as early menarche, late meno-
pause, late childbearing, having fewer children, and low
prevalence of breastfeeding, and unhealthy diets, physical
inactivity or obesity [2,22]. For instance, total fertility
(average number of children per woman) declined in the
last 30 years in Algeria (7.18 children per woman in the
1975–80 period to 2.72 in 2005–2010 period) [23]. More-
over, in two neighboring countries of Algeria, Morocco
and Tunisia, obesity is significantly higher among women
than among men (22.7% vs. 6.7% in Tunisia and 18% vs.
5.7% in Morocco) and prevalence of obesity among
women has tripled over the past 20 years [24]. Half of all
women are overweight or obese (BMI > 25) with 50.9% in
Tunisia and 51.3% in Morocco [24]. BRCA1 and BRCA2
mutations have been identified in Algerian patients. The
pathogenic mutations observed are mainly similar to those
described in European counties except one found in a
family of Kabylia, a northern neighboring region of Setif
[25]. Noteworthy, endometrial and ovarian cancers, which
share risk factors with breast cancer, did not display in-
creases. In particular, ovarian cancer displayed a decrease
in the 45–64 years age group. It is possible that opportun-
istic mammography anticipated the diagnoses of breast
cancer in younger age groups.
Invasive cervical cancer (ICC) is the third most com-
mon female cancer in Setif, and a sharp decline in ICC
incidence was observed mainly in the 15–44 age group.
A potential shift of ICC diagnoses to uterus, unspecified
(near 16% of all uterine cancers in 2006–2010) cannot
explain this decline. The development of cervical cancer
is causally associated to infection by high-risk Human
Papilloma Viruses (HPV). In Algeria, the HPV16 in
single- or multiple-type infection has been shown to be
the predominant HPV type (61.4%) in ICC, followed by
HPV18 (15.8%), and HPV45 (6.4%) [26]. The prevalence
of HPV16 is similar to the prevalence observed in European
or North-American populations [26]. In Setif, the preva-
lence of high-risk HPV was 75%. Moreover, in all agegroups a drop of the squamous cell carcinoma (SCC) histo-
logic subtype (89% of all ICC diagnoses in 1986–1990, vs.
53% in 2006–2010) is observed. This decrease can thus be
ascribed to opportunistic early detection by cytological
screening that is more effective in detecting SCC than
adenocarcinomas [27]. A similar pattern was observed in
the Center of Tunisia after the introduction of regional
cytological screening program [4].
Thyroid cancer (TC) incidence increased in women in
15–44 and 45–64 age groups. In 2006–2010, the most
common form of TC was the papillary sub-type and was
related to most of the increased incidence (19% of all
TC diagnoses in 1986–1990, vs. 49% in 2006–2010).
This is thought to be largely due to increased detection
of small papillary cancers associated to widespread use
of ultrasound and fine needle biopsies [28].
Prostate cancer is the third most common cancer in
men in Algeria. A number of risk factors detected in
Western Algeria can explain the increased trend in pros-
tate cancer incidence, such as high consumption of red
meat, and dairy products, or low consumption of olive
oil, cauliflower, and intake of fruits [29]. Presently pros-
tate cancer incidence is closely linked to increased up-
take of serum prostate-specific antigen (PSA) testing in
western countries, but no data on PSA testing are yet
available to verify this hypothesis in Algeria.
Reduction of stomach cancer incidence is generally at-
tributed to diets rich in fruit and vegetables, improved
preservation of foods, and reduced prevalence of Helico-
bacter pylori [22]. Some discrepant trends across age
groups between gastric cancer and NPC that share a
common risk factor (preserved foods) may suggest a de-
creasing exposure to Helicobacter pylori in the 15–44
age group.
Colon-rectum cancer increased in 45–64 and 65+ age
groups and is the 2nd most common cancer in both
sexes. The adoption of western lifestyles and behaviors
such as consumption of high-fat diets and physical in-
activity could explain the increase of these cancers to-
gether with genetic predisposition [3]. It is possible that
opportunistic early detection contributed to the increase
of incidence in older age groups.
Gallbladder is the 5th most common cancer in Setif
women. Algerian women show the highest rates of
gallbladder cancer as compared to the other Arab
countries where this cancer is generally rare [2]. The
temporal trends showed a favorable pattern in the 15–
44 age group suggesting that differential risk factors
are acting.
The selective increase of non-Hodgkin’s lymphomas in
the 15–44 age group in women is intriguing. Moreover,
further studies are required to elucidate the increase of
leukemias, particularly lymphoid leukemias, in the 15–44
age group.
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and completeness that should be made clear. Firstly,
cancer and comorbidities are extremely common in
elderly people and the percentage of histologically con-
firmed cancers is generally lower among them than in
younger age groups. Although under-diagnosis and under-
registration seem to be unlikely, the complete identification
of true cases in older age groups may be difficult. Secondly,
the accuracy of DCOs depends on coding practices. The
low number of DCO should have limited the possibility of
differential practices influencing death certification proce-
dures. Thirdly, no mortality/incidence ratios were available
(as in all North-African cancer registries). This information
would have given further confidence in the observed re-
sults. Fourthly, due to the relatively small population cov-
ered (1.5 million, i.e. 5% of Algeria’s population), more
accurate results from a bigger cohort are needed.
Among the strengths of the study, MV% reached good
or acceptable levels in the studied cancer sites. Moreover
MV% did not change significantly over time, thus, any
estimated trend in incidence is unlikely to be the conse-
quence of changes in the degree of ascertainment. More-
over, a small proportion of cancer cases were reported
by DCOs. Finally, the availability of complete morph-
ology data provided the opportunity to associate some
trends to potential early detection initiatives.
Conclusions
Some main conclusions can be drawn from the trends of
cancer incidence observed in the last 25 years in Setif.
Besides ageing of the population, temporal variations in
caseload indicate cohort effects due to differential expos-
ure to risk factors and improved detection methodology.
In the light of international recommendations against
cancer [30] three leading priorities can be advocated.
Firstly, in the light of the observed variation in incidence
that may be linked to participation in opportunistic screen-
ings, it is reasonable to promote organized population-
based screening programs aimed at reducing breast,
colon-rectum, and cervical cancers. Secondly, primary pre-
vention intervention at population level must be established
to attempt a reduction in factors such as tobacco smoking
and/or overweight. Thirdly, efforts should focus on the re-
duction of vaccine-preventable cancers. HPV vaccination
for the prevention of cervical cancer should be introduced.
The use of hepatitis B virus (HBV) vaccine for prevention
of hepatocellular carcinoma should also be expanded.
However, the application of these international recom-
mendations against cancer in Setif must take into account
epidemiological transition, lifestyle and environmental
changes, poor health education, and difficult access to
health care facilities. Thus, using evidence-based medi-
cine, AROME project defined the “minimal requirements”
guidelines (vs. standard of care guidelines) to form a basisfor the development of practices and policies for diagnosis
and treatment in limited-resource countries. The guide-
lines included cancers of prostate, bladder, lung, breast,
head and neck, colon-rectum, and cervix [31].
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